Torsten Falk

1.1k total citations
44 papers, 840 citations indexed

About

Torsten Falk is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Neurology. According to data from OpenAlex, Torsten Falk has authored 44 papers receiving a total of 840 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Cellular and Molecular Neuroscience, 18 papers in Molecular Biology and 14 papers in Neurology. Recurrent topics in Torsten Falk's work include Neuroscience and Neuropharmacology Research (15 papers), Nerve injury and regeneration (11 papers) and Neuropeptides and Animal Physiology (10 papers). Torsten Falk is often cited by papers focused on Neuroscience and Neuropharmacology Research (15 papers), Nerve injury and regeneration (11 papers) and Neuropeptides and Animal Physiology (10 papers). Torsten Falk collaborates with scholars based in United States, Germany and Hungary. Torsten Falk's co-authors include Scott J. Sherman, Shiling Zhang, Mitchell J. Bartlett, Robin Polt, Michael L. Heien, Brian S. McKay, Andrea J. Yool, Alexander D. McCourt, Jürgen R. Schwarz and Christiane K. Bauer and has published in prestigious journals such as SHILAP Revista de lepidopterología, Brain and The Journal of Comparative Neurology.

In The Last Decade

Torsten Falk

43 papers receiving 835 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Torsten Falk United States 19 485 398 192 113 84 44 840
Luisa P. Cacheaux United States 9 436 0.9× 510 1.3× 102 0.5× 301 2.7× 60 0.7× 12 1.2k
Kelly A. Aromolaran United States 13 234 0.5× 555 1.4× 63 0.3× 118 1.0× 55 0.7× 23 882
Benjamı́n Torrejón-Escribano Spain 17 264 0.5× 449 1.1× 185 1.0× 201 1.8× 37 0.4× 28 1.1k
Robyn Flynn Canada 15 356 0.7× 378 0.9× 71 0.4× 61 0.5× 115 1.4× 23 822
Céline S. Nicolas France 13 346 0.7× 515 1.3× 36 0.2× 138 1.2× 71 0.8× 23 965
Diane Lucente United States 15 361 0.7× 748 1.9× 143 0.7× 114 1.0× 132 1.6× 29 1.2k
Antonella Borreca Italy 17 313 0.6× 562 1.4× 242 1.3× 233 2.1× 71 0.8× 32 1.2k
Sara Ebrahimi Nasrabady Italy 11 242 0.5× 332 0.8× 245 1.3× 233 2.1× 63 0.8× 13 1.0k
Jiali Pu China 17 158 0.3× 438 1.1× 319 1.7× 167 1.5× 59 0.7× 48 913
A.K.L. Ting Hong Kong 10 374 0.8× 458 1.2× 52 0.3× 64 0.6× 73 0.9× 14 799

Countries citing papers authored by Torsten Falk

Since Specialization
Citations

This map shows the geographic impact of Torsten Falk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Torsten Falk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Torsten Falk more than expected).

Fields of papers citing papers by Torsten Falk

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Torsten Falk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Torsten Falk. The network helps show where Torsten Falk may publish in the future.

Co-authorship network of co-authors of Torsten Falk

This figure shows the co-authorship network connecting the top 25 collaborators of Torsten Falk. A scholar is included among the top collaborators of Torsten Falk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Torsten Falk. Torsten Falk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bartlett, Mitchell J., Michael L. Heien, Kristian P. Doyle, et al.. (2024). The angiotensin (1–7) glycopeptide PNA5 improves cognition in a chronic progressive mouse model of Parkinson's disease through modulation of neuroinflammation. Experimental Neurology. 381. 114926–114926. 1 indexed citations
2.
3.
Szabó, Lajos, Fahad Al‐Obeidi, Mitchell J. Bartlett, et al.. (2023). Structure-Based Design of Glycosylated Oxytocin Analogues with Improved Selectivity and Antinociceptive Activity. ACS Medicinal Chemistry Letters. 14(2). 163–170. 5 indexed citations
4.
Bartlett, Mitchell J., Dong Lu, Michael L. Heien, et al.. (2023). Antagonism of kappa opioid receptors accelerates the development of L-DOPA-induced dyskinesia in a preclinical model of moderate dopamine depletion. Brain Research. 1821. 148613–148613. 4 indexed citations
5.
Bartlett, Mitchell J., et al.. (2023). Automated system for training and assessing reaching and grasping behaviors in rodents. Journal of Neuroscience Methods. 401. 109990–109990. 2 indexed citations
6.
Molnár, G, Mitchell J. Bartlett, Lajos Szabó, et al.. (2022). Design and Synthesis of Brain Penetrant Glycopeptide Analogues of PACAP With Neuroprotective Potential for Traumatic Brain Injury and Parkinsonism. PubMed. 1. 14 indexed citations
7.
8.
Bartlett, Mitchell J., et al.. (2021). Evaluation of microglia in a rodent model of Parkinson’s disease primed with L-DOPA after sub-anesthetic ketamine treatment. Neuroscience Letters. 765. 136251–136251. 4 indexed citations
9.
Hay, Meredith, Robin Polt, Michael L. Heien, et al.. (2019). A Novel Angiotensin-(1-7) Glycosylated Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Inflammation-Related Memory Dysfunction. Journal of Pharmacology and Experimental Therapeutics. 369(1). 9–25. 52 indexed citations
10.
11.
Bartlett, Mitchell J., et al.. (2018). Ten-Hour Exposure to Low-Dose Ketamine Enhances Corticostriatal Cross-Frequency Coupling and Hippocampal Broad-Band Gamma Oscillations. Frontiers in Neural Circuits. 12. 61–61. 32 indexed citations
12.
Bartlett, Mitchell J., Nicholas D. Laude, Kate L. Parent, et al.. (2014). Differential effects of the NMDA receptor antagonist MK-801 on dopamine receptor D1- and D2-induced abnormal involuntary movements in a preclinical model. Neuroscience Letters. 564. 48–52. 13 indexed citations
13.
Yue, Xin, Beatriz Caballero, S. Zhang, et al.. (2013). Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson’s disease. Neuroscience. 258. 385–400. 46 indexed citations
14.
Falk, Torsten, et al.. (2011). Effects of the novel glycopeptide opioid agonist MMP-2200 in preclinical models of Parkinson's disease. Brain Research. 1413. 72–83. 15 indexed citations
15.
Falk, Torsten, et al.. (2011). Vascular endothelial growth factor-B is neuroprotective in an in vivo rat model of Parkinson's disease. Neuroscience Letters. 496(1). 43–47. 44 indexed citations
16.
Falk, Torsten, Shiling Zhang, & Scott J. Sherman. (2009). Vascular endothelial growth factor B (VEGF-B) is up-regulated and exogenous VEGF-B is neuroprotective in a culture model of Parkinson's disease. Molecular Neurodegeneration. 4(1). 49–49. 55 indexed citations
17.
Falk, Torsten, Shiling Zhang, & Scott J. Sherman. (2009). Pigment epithelium derived factor (PEDF) is neuroprotective in two in vitro models of Parkinson's disease. Neuroscience Letters. 458(2). 49–52. 34 indexed citations
18.
McKay, Brian S., et al.. (2006). Retinal pigment epithelial cell transplantation could provide trophic support in Parkinson's disease: Results from an in vitro model system. Experimental Neurology. 201(1). 234–243. 34 indexed citations
19.
Falk, Torsten, et al.. (2003). Developmental regulation of the a-type potassium-channel current in hippocampal neurons: role of the kvβ1.1 subunit. Neuroscience. 120(2). 387–404. 16 indexed citations
20.
Falk, Torsten, et al.. (2001). Viral vector-mediated expression of K+ channels regulates electrical excitability in skeletal muscle. Gene Therapy. 8(18). 1372–1379. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Luisa P. Cacheaux Breakdown of academic impact, for papers by Kelly A. Aromolaran Breakdown of academic impact, for papers by Benjamı́n Torrejón-Escribano Breakdown of academic impact, for papers by Robyn Flynn Breakdown of academic impact, for papers by Céline S. Nicolas Breakdown of academic impact, for papers by Diane Lucente Breakdown of academic impact, for papers by Antonella Borreca Breakdown of academic impact, for papers by Sara Ebrahimi Nasrabady Breakdown of academic impact, for papers by Jiali Pu Breakdown of academic impact, for papers by A.K.L. Ting
Rankless by CCL
2026